ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATMENT OF INFLAMMATORY CONDITIONS

• US 20130149301A1
• Filed: 11/29/2012
• Published: 06/13/2013
• Est. Priority Date: 05/01/2008
• Status: Abandoned Application

• Current Assignee: rEVO Biologics, Inc. (Agence des Participations de l’Etat)
• Original Assignee: GTC Biotherapeutics, Inc.
• Inventors: Meade, Harry M.
• Application Number:
  US13/688,278
• Publication Number:
  US 20130149301A1
• Time in Patent Office: Days
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 16/462 Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
• CPC Class Codes: C07K 16/464 Igs containing CDR-residues from one specie grafted between FR-residues from another
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/41 Glycosylation, sialylation, or fucosylation
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/734 Complement-dependent cytotoxicity [CDC]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention relates to the treatment of inflammatory conditions including atherosclerosis and sepsis. In particular, the invention relates to treatment of these conditions using antibodies.

Claims

1. A method of treating an inflammatory condition comprising administering to a mammal a therapeutically effective amount of a recombinant aglycosylated CD137 antibody or a prodrug thereof or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the antibody is aglycosylated in the constant region of the antibody.

3. The method of claim 1, wherein the antibody is aglycosylated in the variable region and the constant region of the antibody.

4. The method of claim 1, wherein the inflammatory condition is sepsis.

5. The method of claim 1, wherein the inflammatory condition is atherosclerosis.

6. The method of claim 1, wherein the recombinant aglycosylated CD137 antibody is encoded by a transgene DNA construct in a bioreactor organism, said transgene construct comprising a polypeptide domain.

7. The method of claim 6, wherein the DNA construct is actuated by at least one beta-casein promoter.

8. The method of claim 6, wherein the bioreactor organism is a transgenic ungulate.

9. The method of claim 1, wherein the therapeutically effective amount is about 0.01 mg/kg/day to about 50 mg/kg/day.

10. The method of claim 1, wherein the mammal is a human.

11. The method of claim 1, wherein the aglycosylated CD137 antibody is a chimeric antibody.

12. The method of claim 1, wherein the aglycosylated CD137 antibody is a humanized antibody.

13. The method of claim 1, wherein the aglycosylated CD137 antibody is a fully humanized antibody.

14. A method of treating atherosclerosis comprising administering to a human a therapeutically effective amount of an aglycosylated CD137 antibody.

15. The method of claim 14, wherein the therapeutically effective amount is about 0.01 mg/kg.day to about 50 mg/kg/day.

16. The method of claim 14, wherein the CD137 antibody is aglycosylated in the constant region of the antibody.

17. The method of claim 14, wherein the CD137 antibody is aglycosylated in the variable region and the constant region of the antibody.

18. The method of claim 14, wherein the aglycosylated CD137 antibody is a chimeric antibody.

19. The method of claim 14, wherein the aglycosylated CD137 antibody is a humanized antibody.

20. The method of claim 14, wherein the aglycosylated CD137 antibody is a fully human antibody.